… Therefore, in this 6-month open-label observational preliminary study, we set out to … of the
present open-label observational study suggest that treatment with the rivastigmine patch can …

… There is also preliminary evidence that they may improve some … Mild AD patients switching
from rivastigmine patch to non-… to 6-month follow-up for each category of depression and …

… There is also preliminary evidence that they may improve some … to nonrivastigmine oral ChEI
(n = 22) had a mean MMSE … SE) at 6-month follow-up (delta=2.6) in comparison of mild AD …

… rivastigmine patch treatment in Japanese patients with AD is … The results of the present
open-label observational study … (4.5 mg/day or 9 mg/day) with regard to their depressive state and …

… Preliminary evidence also suggests that patients with AD … trials of rivastigmine enrolled in
open-label studies and some … -controlled, 6-month studies demonstrated that rivastigmine at …

… AD patients. (McDermott and Gray, 2012). A current 6-month open-label observational study
… tests, we hypothesized that rivastigmine treatment ameliorates depression-like behaviors by …

… In a 76-week, open-label study, the long-term safety of the 9.5… Preliminary evidence of
Pimavanserine’s antipsychotic … treatment strategies to ameliorate sleep disturbance in AD patients. …

… were found to ameliorate experimental allergic encephalitis-… treatment of depressed AD at
8 weeks, in open-label study of … Finally, some open-label studies with the AChEI rivastigmine …

… Rivastigmine patch ameliorates depression in mild AD: preliminary evidence from a 6-month
openlabel observational study. Alzheimer Dis Assoc Disord. 2013; 27:289–291. …

… , may improve cognitively and show global clinical amelioration in overall functioning. …
rivastigmine patch. The clinical trial IDEAL (a 6-month, double-blind, placebo-controlled study …